$25.84
0.19%
Downside
Day's Volatility :11.75%
Upside
11.58%
0.27%
Downside
52 Weeks Volatility :48.7%
Upside
48.56%
Period | Cg Oncology Inc. | Index (Russel 2000) |
---|---|---|
3 Months | -40.49% | 0.0% |
6 Months | -30.48% | 0.0% |
1 Year | -30.48% | 1.6% |
3 Years | -30.48% | -20.5% |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | 0.0% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | 0.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
Sell
Neutral
Buy
Cg Oncology Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Cg Oncology Inc. | -31.35% | -30.48% | -30.48% | -30.48% | -30.48% |
Moderna, Inc. | 21.0% | 69.6% | -3.52% | -22.13% | 432.73% |
Regeneron Pharmaceuticals, Inc. | 8.73% | 23.09% | 30.09% | 89.11% | 220.71% |
Novo Nordisk A/s | 6.87% | 33.48% | 56.3% | 234.79% | 463.45% |
Vertex Pharmaceuticals Incorporated | 8.2% | 16.21% | 23.31% | 98.04% | 157.88% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Cg Oncology Inc. | NA | NA | NA | 0.0 | 0.0 | 0.0 | NA | NA |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.67 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.57 | 28.57 | 1.46 | 44.24 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.83 | 44.83 | 2.4 | 3.4 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 27.17 | 27.17 | 0.53 | 16.94 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Cg Oncology Inc. | NA | $1.9B | -30.48% | NA | 0.0% |
Moderna, Inc. | Buy | $47.0B | 432.73% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $106.7B | 220.71% | 28.57 | 29.45% |
Novo Nordisk A/s | Buy | $573.2B | 463.45% | 44.83 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $108.1B | 157.88% | 27.17 | 39.46% |
Organization | Cg Oncology Inc. |
Employees | 61 |
CEO | Mr. Arthur Kuan |
Industry | Miscellaneous |
Invesco Ultra Short Duration Etf
$25.84
-9.33%
Blackline, Inc.
$25.84
-9.33%
Arbor Realty Trust, Inc.
$25.84
-9.33%
Fulton Financial Corp
$25.84
-9.33%
Dimensional International Co
$25.84
-9.33%
Arcadium Lithium Plc
$25.84
-9.33%
Taiwan Msci Etf Ishares
$25.84
-9.33%
Amer Sports, Inc.
$25.84
-9.33%
Crane Nxt Co
$25.84
-9.33%